2024 Pharm Exec Top 50 Companies
Jun 14, 2024 · As we noted in last year’s report, Novo Nordisk and Eli Lilly, competing in the lucrative GLP-1 receptor agonist space that, of late, has captivated the US and beyond in weight loss, are knocking loudly on the top-10 door.Both companies, who own the highest market caps, respectively, in pharma, turned in massive growth in our latest Pharma 50.
Pharmaceutical Executive
December 27th 2024. In this part of his Pharmaceutical Executive video interview, Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), explains the ethical considerations of using social media to share personal and professional experiences, especially in a field as sensitive as fertility.
Understanding IDNs and What They Mean to the Pharmaceutical …
Aug 2, 2024 · Integrated Delivery Networks have changed the healthcare landscape over the past decade. Greg Skalicky, president and chief revenue officer at EVERSANA, spoke with Pharmaceutical Executive about the ways that commercialization teams are working with these networks to bring drugs to markets.
2024Finalists - pharmexec.com
Agency: Avant Healthcare Pharmaceutical Company: UCB Campaign: Make HStory (US HCP Campaign) Agency: ClinicalMind Pharmaceutical Company: TruElastin Laboratories, Inc. Campaign: Pushing the limits of aesthetics Agency: MedTrix Healthcare Pharmaceutical Company: Allergan Medical Institute, An Abbvie Company Campaign: The Virtual Patient …
Pharmaceutical Executive - PharmExec
Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.
Biopharma Trends in 2024 and Beyond - PharmExec
Jan 17, 2024 · The Inflation Reduction Act (IRA), mergers and acquisitions, obesity-control drugs, and artificial intelligence (AI) dominated the pharma industry’s headlines in 2023.
FDA Approves Galderma’s Nemluvio for Treating Adults with
Aug 13, 2024 · The FDA has approved Galderma’s Nemluvio (nemolizumab), a subcutaneous injection treatment designed for adults with prurigo nodularis. According to the company, approval was based on results of the Phase III OLYMPIA trials, which followed Nemluvio;’s designation as a Breakthrough Therapy in 2019 and Priority Review status earlier this year.
Amgen's Novel Weight Loss Drug Shows Potential for Longer …
Feb 6, 2024 · Amgen’s novel weight loss drug candidate maridebart cafraglutide (MariTide) showed significant promise in a Phase I trial (NCT04478708), with data suggesting longer lasting and durable reductions in body weight compared with the popular glucagon-like peptide (GLP)-1 agonists currently on the market—Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s …
A Promising Option: Exxua - PharmExec
Aug 16, 2024 · In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE …
22nd Annual Industry Audit: The Pharma Value Picture - PharmExec
Nov 14, 2023 · Welcome to Pharmaceutical Executive’s 22nd annual Pharmaceutical Industry Audit.We present a unique financial performance analysis of the top 15 publicly traded biopharmaceutical companies (“The Nifty Fifteen”) based on 2022 sales revenue and other financial metrics.